FATE: Multiplikator P/S Fate Pharma
The revenue multiple dynamics reported by the GURU.Markets platform confirm that the valuation of Fate Therapeutics, Inc. (FATE) depends on clinical trial outcomes. Growth is supported by iPSC-based NK-cell synthesis technologies and strategic alliances with pharma behemoths to combat tumors. Meanwhile, the 34.20 value serves as a baseline indicator of market expectations, linking current market capitalization to the company's actual sales volumes.
Fate Therapeutics Corp (FATE) - rincian metrik lan laporan keuangan
- rega saham lan prakiraan rega para ahli:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Fate Therapeutics, Inc.|FATE - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Fate Pharma|FATE - Gunggung utang perusahaan|Rasio utang marang aset resik Fate Therapeutics Corp|FATE - Utang jangka dawa perusahaan|Utang jangka cendhak Fate Therapeutics|Rasio jangkoan perantara fatetherapeutics.com
- statistik bathi lan rasio pasar:
FATE - Bathi resik|Proyeksi bathi mangsa ngarep Fate Therapeutics, Inc.|FATE - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake Fate Therapeutics Inc|FATE - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Fate Therapeutics Corp|FATE - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Fate Therapeutics|FATE - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan fatetherapeutics.com|FATE - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Fate Therapeutics, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:fatetherapeutics.com, FATE
Investors must find a balance between operational risks and future returns, given that the Inertia platform establishes a long-term patent foundation for subsequent monetization. Analyzing the price-to-sales ratio allows for an assessment of the business's market value relative to its actual sales, identifying the risk of overpayment or signs of capital stagnation, which confirms the resilience of the technological profile of Fate Therapeutics, Inc. (FATE).
Perusahaan pesaing
ONC: Rasio rega marang dodolan|Multiplikator P/S HALO (Halozyme)|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG: Kapitalisasi marang pendapatan|CG Oncology Therapeutics - Kapitalisasi marang volume dodolan|URGN: Multiplikator P/S|Rega marang dodolan bicara.com (BCAX)|Kapitalisasi marang pendapatan PSNL|ERAS: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan DCTH (Delcath)|Kapitalisasi marang volume dodolan YMAB|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Rasio kapitalisasi pasar marang pendapatan CADL|Accuray - Multiplikator P/S|Rega marang dodolan SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|Citius Oncology Inc - Rasio kapitalisasi pasar marang pendapatan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|Multiplikator P/S protaratx.com|Rasio rega marang pendapatan Aadi Bioscience Inc (WHWK)|TCRX: Rasio rega marang dodolan|Multiplikator P/S CSBR (Champions Oncology, Inc.)|XBiotech Inc (XBIT) - Rega marang dodolan|CVM: Kapitalisasi marang pendapatan|OSTX - Multiplikator P/S|RADX (Radiopharm Theranostics) - Kapitalisasi marang pendapatan|ARTV: Kapitalisasi marang volume dodolan|ANL (Adlai Nortye Ltd) - Multiplikator P/S|Veru Corporation (VERU) - Koefisien rega marang pendapatan|Multiplikator P/S TPST|Kapitalisasi marang pendapatan xiliotx.com XLO|Rasio rega marang pendapatan Renovaro RENB|Koefisien rega marang pendapatan Mural Oncology PLC (MURA)|KAPA: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OKUR (OnKure Therapeutics Inc)|GDTC: Multiplikator P/S|CRIS - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Apollomics Inc.|Rasio kapitalisasi marang pendapatan THAR (Tharimmune Inc)|Multiplikator P/S ADVB|Kapitalisasi marang pendapatan Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sunshinebiopharma.com (SBFM)|Xenetic Bio - Multiplikator P/S|Rasio rega marang dodolan SLRX|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|Kapitalisasi marang pendapatan BGNE|CKPT (checkpointtx.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S ELEV|ICAD - Rega marang dodolan|Multiplikator P/S IKNA (Ikena Oncology)|NTBL - Kapitalisasi marang pendapatan|Viracta - Multiplikator P/S|MOR - Multiplikator P/S|NAYA Biosciences Inc. (NAYA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan AAPGV
